Home > Resources > Whitepapers > Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

MedTech, Industrial Impact

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Spotlight

Oxford Nanopore Technologies Ltd

Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field.

OTHER WHITEPAPERS

THE RNA PLATFORM

whitePaper | May 26, 2022

Exploring biomarkers with the new central dogma. It can be a daunting decision for scientists to know when to focus on DNA, messenger RNA (mRNA), non-coding RNA (ncRNA) or protein biomarkers for routine clinical use, with each exhibiting its own strengths and limitations

Viral Vectors as a Gene Delivery Vehicle

whitePaper | August 5, 2022

The field of gene and cell therapy is experiencing a renaissance, with innovations in the use of viral vectors as a gene delivery vehicle being a key factor in the field’s growth.

Lipid Nanoparticle and Liposome

whitePaper | September 12, 2022

Lipid nanoparticles (LNPs) and liposomes are variations of lipid-based drug carriers differing in their internal structure.

The biopharmaceutical industry is leading the way in developing vaccines and treatments for COVID-19

whitePaper | April 8, 2020

The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza.

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

More Whitepapers